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Abstract
Background: GALI or Global Activity Limitation Indicator is a global survey instrument measuring participation
restriction. GALI is the measure underlying the European indicator Healthy Life Years (HLY). Gali has a substantial
policy use within the EU and its Member States. The objective of current paper is to bring together what is known
from published manuscripts on the validity and the reliability of GALI.
Methods: Following the PRISMA guidelines, two search strategies (PUBMED, Google Scholar) were combined to
identify manuscripts published in English with publication date 2000 or beyond. Articles were classified as reliability
studies, concurrent or predictive validity studies, in national or international populations.
Results: Four cross-sectional studies (of which 2 international) studied how GALI relates to other health measures
(concurrent validity). A dose-response effect by GALI severity level on the association with the other health status
measures was observed in the national studies. The 2 international studies (SHARE, EHIS) concluded that the odds
of reporting participation restriction was higher in subjects with self-reported or observed functional limitations. In
SHARE, the size of the Odds Ratio’s (ORs) in the different countries was homogeneous, while in EHIS the size of the
ORs varied more strongly. For the predictive validity, subjects were followed over time (4 studies of which one
international). GALI proved, both in national and international data, to be a consistent predictor of future health
outcomes both in terms of mortality and health care expenditure. As predictors of mortality, the two distinct health
concepts, self-rated health and GALI, acted independently and complementary of each other. The one reliability
study identified reported a sufficient reliability of GALI.
Conclusion: GALI as inclusive one question instrument fits all conceptual characteristics specified for a global
measure on participation restriction. In none of the studies, included in the review, there was evidence of a failing
validity. The review shows that GALI has a good and sufficient concurrent and predictive validity, and reliability.
Keywords: Disability, Participation restriction, Healthy life years, Validity, Reliability, Summary measure of population
health, GALI
Introduction
Ageing of populations defies health and social policies.
Population ill-health and especially disability are major
challenges as there is currently no consistent evidence
that the lengthening of life expectancy goes with a
reduction in the total lifetime days of disability, the
so-called compression of morbidity [1].
The concept of disability is complex and multidimen-
sional. In initial medical models, disability was viewed as a
problem residing solely in the persons affected. Disability
referred to consequences of chronic or acute diseases or
accidents on the functioning of specific body systems and
on mental, physical and sensory functions in terms of (1)
impairment or dysfunctions and structural abnormalities
in specific body systems; (2) disability or restrictions in
basic physical and mental actions and (3) handicaps or
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difficulties in doing activities of daily life [2–5]. More
biophysical-social models introduce the person-environment
perspective of the disablement process: disability as the
outcome of the interaction of a person and his environ-
ment [6] and the dynamics of disability which is af-
fected by how a person’s capacity fits the environmental
demand and results in participation [3]. Participation
restriction is defined as limitations in the performance
of roles and social involvement in different settings
such as work and employment, school, leisure, parent-
ing, housework, community, social and civic life [7]. Be-
cause participation is influenced by environmental
factors and social norms, any measure of participation
restriction cannot differentiate the impact of the im-
pairment and functional limitations from the impact of
accommodations and enabling environments [8, 9].
Disability can occur in any human activity and set-
tings. Adding to this complexity, instruments measuring
disability differ in the domains of functioning included,
in their goals to measure either capacity (without any
personal or equipment assistance) or performance (with
assistance), or to measure also disability symptoms (pain,
weakness, endurance, …), levels of severity or the dur-
ation of the disability. Traditional survey instruments
measure a limited number of tasks (5 to 7) in the do-
main of personal care (ADL (Activity of Daily Living)) or
in the domain of household management (IADL (Instru-
mental ADL)). Other survey instruments have either in-
creased the number of disability questions by adding
more and more tasks [10] or have developed short set of
disability questions that have good coverage of activities
[11, 12]. At the same time there has been a quest to
measure disability with parsimony similar to the parsi-
mony in measuring health using the global one-item sur-
vey instrument on self-rated health (SRH) [13, 14].
In response to the call for parsimony, a global survey in-
strument to measure disability, the Global Activity Limita-
tion Indicator or GALI, was proposed. The development
of GALI occurred in the framework of the creation of a
coherent set of indicators to monitor health across Europe
[15]. GALI was part of set of 10 survey instruments in-
cluding three global one-item survey instruments were
proposed covering distinct health concepts: perceived
health, chronic morbidity and participation restriction
[16]. The 3 global questions define the Minimum Euro-
pean Health Module (MEHM) [17]. At the time of the de-
velopment of the GALI, the beta version on the
International classification of Functioning, Disability and
Health (ICF) served as conceptual framework [6, 18, 19].
Because of its implicit reference to the ability for societal
participation in a variety of non-specified settings and
non-specified domains of life (such as employment,
school, housework, and leisure) using the wording “activ-
ities people usually do”, GALI is intended to be a global
self-reported measure of participation restriction. Add-
itional conceptual criteria were the health relatedness of
the cause of disability, the generic normative comparison
in the level of participation, the long-standing duration of
the disability (a duration of at least 6 months) and the
ability to measure levels of severity [15, 18]. To accommo-
date the results of cognitive testing in relation to the se-
verity options in the answer categories, the wording “to
what extent” was added in the final version [20]:
“For at least the past 6 months, to what extent have
you been limited because of a health problem in
activities people usually do?”
Would you say you have been: severely limited,
limited but not severely, or
not limited at all?
Being part of the MEHM, GALI is used in major Euro-
pean health and non-health surveys such as the Euro-
pean Health Interview Survey (EHIS), Survey on Income
and Living Conditions (SILC) and the Survey of Health,
Ageing and Retirement in Europe (SHARE). Since 2004,
GALI is also the underlying measure of the European in-
dicator “Healthy Life Years (HLY)”. HLY is a measure of
disability free life expectancy and was presented in the
set of structural indicators selected and defined to help
measure progress in strategic European policies such as
the 2000 Lisbon strategy and the European 2020 strategy
on Active and Healthy Ageing [21]. HLY is one of the
components of the Active Ageing Index [22]. At the na-
tional level, countries such as France, have selected HLY
as one of their high level indicators for long term evalu-
ation of their economic, social and environmental pol-
icies [23]. GALI also fits the requirement to follow-up
European and United Nations disability policies, that
stress the importance of full and effective participation
as main policy outcome [24, 25]. More recently, GALI,
as underlying health measure of HLY, contributes to the
scoreboard indicators of the European Pillar of Social
Rights [26] . Due to its high informational value, its rela-
tive simplicity and its compliance elaborated by the
European Union, HLY has been proposed to be the in-
strument in designing social security solutions [27].
Given the use of GALI within the European Union, es-
pecially the fact that it is the measure underlying the
European indicator HLY, the objective of current paper
is to bring together what is known from published man-
uscripts on the validity and/or the reliability of GALI.
Construct validity evaluation has been divided into
translation validity, a more qualitative process and criter-
ion validity, a quantitative approach [28]. Current review
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focus on the quantitative validity, as translation validity
is linked to the conceptual criteria used for the GALI de-
velopment [9, 15].
Methods
Two search strategies were combined by HVO and NB
in January 2017 to identify peer reviewed manuscripts
published in English with publication date 2000 (the
period GALI was developed) or beyond. Following the
PRISMA guidelines, manuscripts were independently
evaluated by HVO and NB first on the titles and ab-
stracts and in a second stage on the text. The result of
the search and manuscript selection is summarized in a
PRISMA flow chart (Fig. 1) [29]. First, PUBMED data-
base (https://www.ncbi.nlm.nih.gov/pubmed) was used
with {“global activity limitation”[All Fields] OR
(GALI[All Fields] NOT GALI[Author])} as search proto-
col. Of the 69 publications 54 were excluded: content
not related to the topic (e.g. Gali as part of a name of a
butterfly “Calisto franciscoi Gali”), language other than
English, Gali in name, email or contact address of one of
the authors). Of the remaining 15 articles, 9 articles were
retained as manuscripts studying the validity or reliabil-
ity of GALI. A second search used the Google Scholar
database (https://scholar.google.com/) using as search
protocol “global activity limitation”. Of the 208 refer-
ences 107 were excluded (content not related to the
topic, language other than English, only an abstract, and
citations). The remaining 101 articles were screened to
identify manuscripts published with the objective to esti-
mate the validation or reliability of the GALI (N = 11).
Double publications were excluded (N = 2). The double
publications were a result of the publication of institu-
tional working papers or reports prior to the publication
of a manuscript in a scientific journal. All 9 manuscripts
retained were found in both databases. Manuscripts
were grouped as reliability studies, concurrent validity
studies (cross-sectional studies measuring an associ-
ation) or predictive validity studies (ability of GALI to
predict an outcome) [28]. We further distinguished be-
tween national and international studies, as international
studies may be more sensitive to total survey error due,
for example, to the lack of international harmonization
at different stages of the study [30].
Results
The classification of the manuscripts by type of study is
given in Table 1.
Concurrent validity
Concurrent validation studies are cross-sectional studies
with the objective to measure how GALI relates to other
health measures. As there is no gold standard, the asso-
ciations are mainly measured using other health compo-
nents such as chronic (co)morbidity or other dimensions
of the disablement process, e.g. functional limitations in
Fig. 1 PRISMA flow chart [29]: validation and reliability studies of the Global Activity Limitation Indicator (GALI) selection, 2000–2017
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activities. Two studies were national [31, 32] and 2 were
international [33, 34]. In one of the international studies,
GALI could be evaluated against the results of objective
measures of functional limitations [34]. The age groups
included in the studies varied between subjects 15 years
and older, 50 years and older or 65 years and older. One
of the international studies focused on the population
15 years and older but provided, for comparison pur-
poses, tables and graphs for the population 50 years and
older as supplementary material [33]. The national stud-
ies considered GALI by severity level, while the inter-
national studies ignored the severity level.
Van Oyen et al. used the 2001 Belgian Health Interview
survey [32] to evaluate GALI against (1) Activities of Daily
Living (ADL) limitations (categorical by level of severity,
and by number of limitations); (2) the Short Form Survey
(SF-36) physical domain score; (3) the number of
self-reported chronic physical conditions out of a list of 29;
(4) the number of mental conditions (depression, anxiety,
somatization, sleep disorders) based on 4 subscales of the
Symptoms Check List (SCL-90R) and (5) a mental
well-being score using the General Health Questionnaire
(GHQ-12). A composite morbidity indicator (CMI: catego-
rized as no illness, only mental, only physical illness and
both) was used to measure the associations stratified by the
ADL functional limitation status. The results indicated that
all health indicators were positively associated with GALI.
The participation restriction distribution by severity level
was positively associated with both the number and severity
of ADL limitations, the SF-36 physical domain score, the
number of chronic conditions and the mental health indi-
cators (mental health comorbidity score or the GHQ-12).
E.g., without any ADL limitations the predicted probability
distribution of being without, with mild or with severe par-
ticipation restriction was respectively 0.82, 0.15, 0.03 com-
pared to 0.20, 0.43, 0.37 and 0.13, 0.38, 0.49 in people with
at least one ADL limitation or with at least one severe ADL
limitation. When people were limited in 6 ADLs, the GALI
probabilities of reporting no, mild and severe restrictions
were respectively 0.03, 0.10 and 0.87. Using the GHQ-12
mental well-being score, the predicted probabilities of no,
mild and severe GALI restrictions changed from respect-
ively 0.82, 0.14, 0.04 (best GHQ-12 score) to 0.36 0.36 0.28
(worst GHQ-12 score). The CMI was associated with par-
ticipation restriction both in people with and without ADL
limitations. In the population free of ADL limitations, and
compared to subjects reporting non illness, the participa-
tion restriction prevalence and especially the prevalence of
being severely restricted increased gradually in people
reporting only mental illness, reporting only physical illness
or reporting both mental and physical illness. A similar
trend was observed in subjects with ADL limitations but
the prevalence of participation restriction and severe re-
striction was substantially higher within each morbidity
level. E.g., the predicted probability of no participation re-
strictions in subjects without ADL limitations and without
any mental or physical illness was 0.95 and dropped to re-
spectively 0.90, 0.80 and 0.57 in subjects reporting only
mental illness, only physical illness or both; in people with
ADL limitations the predicted probabilities of no participa-
tion restriction were respectively 0.46, 0.43, 0.37 and 0.12.
The second concurrent validation study used the 2006
Spanish National Health Survey but included only sub-
jects 65 years and older to test (1) if GALI is primarily
correlated with functional disability and secondarily with
morbidity, and (2) if Self Rated Health (SRH), in con-
trast, is primarily correlated with morbidity and second-
arily with functional disability [31]. Associations were
sought with a functional comorbidity indicator (FCI)
based on a list of 16 chronic conditions including obes-
ity, hearing and visual impairments, the GHQ-12 for
mental ill-health and a functional disability measure
(based on 27 items related to IADL/ADL and mobility).
The Spearman correlation coefficients of FCI, GHQ-12
and functional disability were 0.35, 0.45 and 0.58 with
GALI compared to 0.46, 0.44 and 0.36 with SRH. The
predicted probability of participation restriction indi-
cated a greater effect in function of the number of func-
tional disabilities compared to the comorbidity indicator
while the inverse was observed for the predictive prob-
ability of not being in very good/good SRH. The pre-
dicted probabilities for GALI and SRH were similar in
function of the GHQ-12. Compared to subjects with no
functional disability (ADL/IADL or mobility), the multi-
nomial odds ratios (MORs) of participation restriction
and severe participation restriction were respectively
1.44 and 2.02 in subjects with one functional disability
(ADL/IADL or mobility) and respectively 8.94 and 64.84
when limitations in 11 functions were reported. The
MORs for participation restriction and severe participa-
tion restriction were respectively 1.96 and 2.00 for sub-
jects with a FCI score of 1 and respectively 7.49 and 7.96
for people with a FCI score of 7. The MORs of having
participation restriction and severe participation restric-
tion in people with a GHQ-12 score of 1 and of 7 were
respectively 1.32 and 1.61; and 3.42 and 8.05. The MORs
of fair SRH and very poor/poor SRH indicated a similar
pattern but were more extreme in function of the func-
tional comorbidity score while less extreme in function
of the functional disability indicator. These results sug-
gest that GALI was primarily a measure of functional
status and secondarily a measure of physical and mental
morbidity whereas for SRH, physical morbidity and to a
lesser extend mental morbidity were the main correlates.
The two concurrent international studies [33, 34]
followed a similar statistical analysis plan using the data
from SHARE and EHIS: the estimation of the predicted
GALI probability distribution by fitting logistic regression
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and random-effects meta-analysis models to evaluate het-
erogeneity of the association between countries (Table 1).
The 2004 SHARE study covered 11 EU countries [34],
while the EHIS (2007–2010) used data from 14 EU coun-
tries [33]. Main differences are related to the age groups in-
cluded, the use of observed measures and the stronger
overall survey design homogeneity between countries in
the SHARE survey compared to the EHIS survey design. In
both studies, the severity level information of GALI was ig-
nored in the analysis. The GALI was evaluated against the
number of ADL and IADL limitations. The EHIS data also
provided an evaluation against a function limitation meas-
ure by severity based on the self-reported moderate or se-
vere problems in at least one of the following 6 functions:
walking a certain distance, going up and down the stairs,
carrying in the hands or arms, using hands and fingers to
manipulate small objects, biting and chewing. The objective
instruments to evaluate the validity of the GALI in SHARE
measured the hand grip strength and the walking speed (in
75 years or older only; reported walking limitations in those
50–74 years). In the SHARE study, the probability of the re-
ported participation restriction was lower when the grip
strength or walking speed were higher. Similarly, and in
both studies, the probability of having participation restric-
tion was higher as the number of ADL or IADL limitations
increased or if the level of severity of those limitations in-
creased (EHIS only). In all countries and in both studies,
the direction of the association, measured as ORs, between
GALI and the other health measures was as expected. That
is: the odds of reporting participation restriction is higher
in subjects with poorer functioning and disability measures
(either in function of the ADL, IADL, the physical func-
tional limitations or in function of low hand grip strength
or walking speed). In the population 50 years and over, the
overall random effect meta-regression ORs were less ex-
treme in the SHARE study compared to the EHIS: e.g.
comparing subjects with at least one ADL-limitation vs.
those with none, the combined OR of having participation
restriction were 8.3 in SHARE and 12.3 in EHIS; with re-
spect to IADL limitations, the combined ORs were respect-
ively 6.4 and 9.1. In the SHARE study, there was no
significant country variation in the ORs in function of
ADL, hand grip strength and walking speed. For IADL in
the SHARE and for all functions and disability measures in
the EHIS, the OR of having participation restriction was
more pronounced in some countries compared to others,
providing evidence of heterogeneity in the effect size.
Predictive validity
The predictive validity of GALI was reported by 4 studies
(Table 1). One study evaluated the predictive effect on
health care expenditure in Belgium [35]; the other 3 stud-
ies focused on mortality. Two of the mortality follow-up
studies used Belgian Health Interview Surveys as baseline
(HIS-2001 [36], HIS-2008 [37]) while the other used the
international SHARE study, wave 2004 and wave
2006/2007 [38]. The duration of mortality follow-up ranged
from 2 to 3 years [37, 38] to 10 years [36]. Two of the 3
mortality studies used GALI by severity level [36, 38]. The
age considered ranged from 15 years and older [36] to
50 years and older [38] and 65 years-plus [37]. In all 3 mor-
tality studies, the predictive capacity of GALI was set off
against the predictive capacity of SRH. The 3 studies identi-
fied GALI and SRH as complementary predictors of mor-
tality, indicating that GALI and SRH share some traits but
add different dimensions: health and disability. In the two
studies with a short follow-up period [37, 38], adjusting for
age, education and life style (SHARE only: physical activity,
smoking, BMI) both GALI and SRH were significant pre-
dictors of mortality: having participation restrictions dou-
bled (mild) and tripled (severe) the mortality rate in
SHARE, while the mortality rate increased by a factor of
2.4 when no severity level was accounted for in the Belgian
study [37]. In the Belgian study [37], when both GALI and
SRH were included in the Poisson regression model, GALI
remained a significant predictor of mortality next to SRH
in both males and females, while SRH remained only sig-
nificant in males. In the SHARE follow-up [38], the
fully-adjusted proportional hazard model, controlling for
specific morbidity indicators (asthma, cancer, depression)
and disability measures (mobility, IADL), GALI and SRH,
showed that SRH remained significantly associated with
mortality only in men while GALI remained significantly
associated with mortality only in women. Over a 10-year
follow-up period [36], GALI as well as SRH were strong
predictors of mortality. Adjusting for age, gender and
socio-economic position, people with mild and severe par-
ticipation restriction, compared to no participation restric-
tion, had mortality rate ratio’s (MRR’s) of respectively 1.8
and 3.0. Compared to good/very good SRH the MRR in
subjects with fair and bad/very bad SRH the MRR was re-
spectively 1.8 and 3.6. When including GALI and SRH in
the model, both remained significant predictors of mortal-
ity: MRR for GALI were: 1.4 (mild) and 1.8 (severe); and
MRR for SRH were: 1.5 (fair) and 2.5 (bad/very bad). The
predictive ability did not change with gender or
socio-economic position. However, in older subjects, the
predictive ability of SRH was not as strong. The impact on
mortality of both GALI and SRH decreased over time but
remained statistical significant in truncated follow-up pe-
riods: 0–3 years, 3–6 years and 6–10 years.
Van der Heyden et al. evaluated how GALI predicted
health care expenditure using data linkage between each
participant to the 2008 Belgian Health Interview Survey
and the national health insurance data for the 12 months
following the date of the interview [35]. Participation re-
striction was a strong determinant of the total health
care expenditure: e.g. the population with participation
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restriction (21% of the population) accounted for 49% of
the total health expenditure; for severe restriction (5% of
the population) this was 17% of the total expenditure.
The association was stronger for the reimbursed health
care cost compared to the out-of-pocket payments. In
subjects with no chronic conditions compared to people
without participation restriction, the cost ratio of the re-
imbursed cost in subjects with mild or severe participa-
tion restriction was respectively 2.5 and 4.2. In people
with one chronic condition or in people with ≥2 chronic
conditions the cost ratio compared to no participation
restriction were respectively 1.5 and 1.7 in subjects with
mild participation restriction and 2.4 and 3.2 in people
with severe participation restrictions. The authors
decomposed the health expenditure gap between people
with and without participation restriction: differences in
the age distribution (20%) and in the prevalence of
chronic diseases (22%) between the two groups were the
main contributors to the explained differences (48%).
Next to the confounding effect of age, the decompos-
ition analysis also indicated that the impact of age on
health expenditure differed by GALI severity level, sug-
gesting an interaction effect of age. However, in the un-
explained component, the coefficient of chronic
conditions did not differ significantly between GALI cat-
egories, suggesting that chronic conditions in people
with participation restrictions do not result in significant
different health care expenditure compared to people
without participation restrictions.
Reliability
Only one study evaluated the reliability of GALI as part
of the evaluation of the MEHM [39]. The study used the
Belgian 2004 Food Consumption Survey in which people
were visited twice at home by the interviewers. The
interquartile range between the 2 visits was 17–26 days
with median time of 20 days. Both the Pearson correl-
ation (0.73) and the weighted Kappa coefficient (0.68) in-
dicated an acceptable reliability. The stratification by
gender showed a higher Kappa coefficient among males
(0.82) compared to females (0.54). The agreement did
not statistically differ by age (15–64 vs. 65+), by educa-
tion (technical secondary or less vs. general secondary or
higher), by language (Dutch vs. French) or time span be-
tween the interviews (≤20 days vs. > 20 days).
Discussion
Defining disability is not easy. Because it interweaves med-
ical and social domains [40], the concept of disability has led
to divergent interpretations and uses [41]. People may ex-
perience disability due to health in any human activity; yet,
activities included in traditional instruments with focus on
ADL and/or IADL cover only a fraction of all activities [12].
The challenges of measuring disability have been tackled by
two distinct approaches. One option is to include more ac-
tivities, more specific answer categories, more aspects such
as disability symptoms and disability in more specific set-
tings of life [10, 42, 43]. This option induces increased re-
spondents burden, increased survey cost, more complex
analysis in order to provide condensed indicators for end
users. The other option seeks short sets and/or a one single
global instrument [11, 15]. GALI has been nominated the
champion in parsimony [12], but the lack of simplicity and
the high density of concepts in one single question may
hamper its acceptability [9, 44]. Three different alternatives
(decomposing GALI using filtered and routed questions or
through omitting features such as the duration of the dis-
ability and/or the health relatedness) and the original GALI
were evaluated against the short version (including 4 func-
tional limitation questions) of the Washington Group on
Disability instrument [11]. The four variants were randomly
assigned to survey participants (N= 3009). The results, indi-
cating a substantial higher sensitivity of GALI, no evidence
for a better understanding of the simplified alternatives but
possibly, a small advantage in specificity when bringing the
duration of the participation restriction to subsequent ques-
tions, should be balanced against the cost of breaking an
established chronological series [45]. Currently, Eurostat fol-
lows for the upcoming EHIS wave III (2018–2019), the rec-
ommendation of the EHLEIS working group on the
blueprint for an internationally harmonized Summary Meas-
ure of Population Health [9]. The EHLEIS working group,
including experts from the EU, Japan, USA, OECD and
WHO met 3 times (2012, 2013 and 2014) in Paris and pro-
posed that of the different components of disability, partici-
pation restriction in the first place and, in addition,
functional limitations should be the main goals for inter-
nationally harmonized global measures [9]. GALI fits the six
conceptual characteristics specified by the working group: 1.
comprehensive content of participation; 2. measure of
participation performance with current accommoda-
tion; 3. health relatedness of the cause of participation
restriction; 4. normative comparison in the level of par-
ticipation; 5. long-term duration of restriction; 6. meas-
ure severity of restriction in the response scale (at least
three levels). As mentioned above, this comes at a cost
of lack of conciseness and simplicity.
Of the 3 global questions that constitutes the MEHM
[15], studies reporting on the concurrent and predictive
validity and reliability of SRH have the longest history
[46–48], while less evaluations have been done with re-
spect to the global question on chronic disease [49].
In this manuscript, we summarize for the first time the
current evidence of the validity of GALI including concur-
rent and predictive validity studies and reliability studies.
Current review has limitations. A first limitation of the
review is that it only included peer-reviewed manuscripts
published in English, identified using only one bibliographic
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database in addition to Google Scholar. Google Scholar was
used to search also the grey literature. The authors were in
close contact with the international research network on
health expectancies and the disablement process (REVES).
Members of the REVES network were invited to participate
in a survey [9] with the aim to identify additional manu-
scripts. Secondly, all studies included rely on self-reported
measures and the precision of the validity and reliability es-
timates relies upon accurate reporting. Thirdly, no quality
related weighting was applied in describing the different
manuscripts. E.g in contrast to the mortality follow-up in
Belgium [36], the mortality follow-up within SHARE [38]
did not use register data resulting in an under-numeration
of the number of deaths. A possible effect of a selection bias
on the predictive power of GALI and SRH on mortality
cannot be excluded, but if any, the text of the manuscript
claims it should be limited [38]. Next, the review was ham-
pered by the methodological heterogeneity of the different
studies: e.g. the association of GALI with health indicators
in the two national concurrent validations studies [31, 32]
was measured using different health indicators and different
statistical modeling. Finally, the review was not registered.
To summarize, in none of the 9 studies included, there
was evidence of a failing validity. The concurrent validity
was evaluated in 4 studies. The two national concurrent
validation studies indicated a dose-response effect by
GALI severity level on the association with other health
status measures with a somewhat weaker association re-
lated to the mental well-being score.The two inter-
national studies did not consider the GALI severity level.
They concluded that the odds of reporting participation
restriction were higher in subjects with self-reported or
observed functional limitations. The strength of the as-
sociation varied more strongly between the countries
using the EHIS compared to the SHARE survey. The dif-
ference in homogeneity can in part be explained by the
variation in the implementation of the EHIS, including
different wording across countries [33]. International
comparability of data submitted to Eurostat, including
those on GALI is hampered as EU regulations does not
include guidelines on the exact formulation of the ques-
tions within one and between surveys [20] nor on the
data collection mode increasing the likelihood for differ-
ential total survey errors [30]. This under-valorizes the
substantial efforts done by Eurostat to harmonize instru-
ments in surveys [49]. Differences in accounting for the
institutionalized population may further have affected
the heterogeneity in the size of the association of the
GALI with other health measures [50]. Although, with-
out focus on validity, a recent study, using the 2013 Da-
nish Health and Morbidity survey and 31 health-related
indicators, corroborates the concurrent validity describ-
ing a trend towards poorer health and wellbeing in sub-
jects with more participation restriction as well as a
trend toward a less healthy life style or less contacts with
social relations in function of more participation restric-
tions [51]. Using follow-up data, GALI proved both in
national and international studies to be a consistent pre-
dictor of future health outcomes both in terms of mor-
tality and health care expenditure. As predictors of
mortality, the two distinct concepts - SRH and GALI -
acted independently and complementary of each other.
Only one reliability study was identified indicating a suf-
ficient reliability of GALI.
Conclusion
The strength of GALI as an inclusive one-question instru-
ment is that it fits all conceptual characteristics specified
for a global measure on participation restriction. The re-
view indicates that current version of GALI has a good and
sufficient concurrent and predictive validity and reliability.
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